Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SARomics Biostructures and Red Glead Discovery Enters into Drug Discovery Collaboration

Published: Thursday, October 25, 2012
Last Updated: Thursday, October 25, 2012
Bookmark and Share
The companies will perform a joint collaborative project with the goal of developing novel lead compounds against epigenetic pathway targets.

SARomics Biostructures and Red Glead Discovery have announced that they have entered into a drug discovery collaboration.

Targeting proteins involved in epigenetic mechanisms (the cellular processes associated with the modification of chromatin) have emerged as an important new therapeutic opportunity for treating cancer, diabetes, inflammatory diseases and more.

By merging the unique and highly complementary capabilities of the two companies, an efficient and versatile fragment-based lead discovery (FBLD) platform is enabled.

The advanced structural biology platform and expertise contributed by SARomics Biostructures are combined with the bioassay technology and medicinal chemistry skills of Red Glead Discovery.

The scientific excellence of the alliance is reflected by the track record of Red Glead Discovery for delivery of lead compounds and the established platform for structure-based drug design implemented by SARomics Biostructures.

For the project, the companies will share costs and the generated intellectual property rights.

Project progress and the discovery of lead compounds will be effectuated by utilization of FBLD, which is a powerful alternative to costly and resource-intensive high-throughput screening (HTS) campaigns.

At this stage of the project, the collaboration will be run without external financing.

Björn Walse, CEO of SARomics Biostructures, said “We are excited about the opportunity to work with Red Glead Discovery on this frontline project that clearly leverages the competitiveness of both companies. We see this initiative as highly complementary to SARomics’ other collaborations, such as those within KINOMED, which focus on protein kinase off-the-shelf crystal structures and fragment complexes.”

Johan Evenäs, CEO of Red Glead Discovery, added “I am convinced that we have a perfect match of competences and experiences enabling a project that would have been difficult for either company alone at this stage. We expect the close proximity of our two companies within the Lund Life Science Incubator at Medicon Village to further facilitate effective collaboration.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A New EU-Funded Industry-Academia Drug Discovery Partnership Targets Challenging Kinases
Industry and academia join to create the Translational Kinase Tumor Inhibitor Discovery Consortium.
Wednesday, April 10, 2013
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
The Epigenetic Influences of Chronic Pain
Researchers at Drexel University College of Medicine are aiming to identify new molecular mechanisms involved in pain.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Mothers Obesity Could be Passed on in mtDNA
Obesity can predispose offspring in multiple generations to metabolic problems.
New Imaging Method Reveals Nanoscale Details about DNA
Enhancement to super-resolution microscopy shows orientation of individual molecules, providing a new window into DNA’s structure and dynamics.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
Naked Mole Rat Exhibits “Extraordinary” Cancer Resistance
Scientists are getting closer to understanding the anti-cancer mechanism of the naked mole rat by making induced pluripotent stem cells.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!